title: Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
abstract: OBJECTIVE
  To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment.
  
  
  METHODS
  This prospective, 3-year follow-up of consecutive patients started on treatment with RLAI in normal clinical practice between August 2002 and September 2003 obtained demographic and clinical data from case notes, prescription charts, and hospital computer records. To determine predictors of continuation, a proportional hazards regression (Cox) model was constructed.
  
  
  RESULTS
  The study included 211 evaluable patients. Over 3 years, 84% of subjects discontinued RLAI; 27.7% of these switched to oral risperidone. The Cox model showed that younger age (p = .001), longer duration of illness (p = .001), inpatient status at initiation (p = .002), and an RLAI dose of 25 mg/2 weeks (p < .001) predicted greater probability of discontinuation.
  
  
  CONCLUSIONS
  A small proportion of patients initiated on treatment with RLAI continued for 3 years. Outcome is likely to be improved by targeting RLAI treatment at specific patient groups and by using a dose of more than 25 mg/2 weeks.
authors.affiliation: Pharmacy Department, Maudsley Hospital, London, UK. david.taylor@slam.nhs.uk
authors.forename: David M
authors.initials: DM
authors.lastname: Taylor
authors.forename: Catrin
authors.initials: C
authors.lastname: Fischetti
authors.forename: Anna
authors.initials: A
authors.lastname: Sparshatt
authors.forename: Arwel
authors.initials: A
authors.lastname: Thomas
authors.forename: Delia
authors.initials: D
authors.lastname: Bishara
authors.forename: Victoria
authors.initials: V
authors.lastname: Cornelius
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015331:Cohort Studies; D003692:Delayed-Action Preparations; D004739:England; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology / Q000706:statistics & numerical data; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy*; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone